Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Shrugs Off Lirilumab Phase II Mono Trial Failure; Eyes Combo Trials

Executive Summary

Bristol says its combination development program for lirilumab - licensed from Innate Pharma in 2011 – remains unaffected by news the anti-KIR checkpoint inhibitor failed in a Phase II trial in elderly patients with acute myeloid leukemia as a maintenance monotherapy.

You may also be interested in...



Innate Adds To IO Pipeline With Novo's First-In-Class Anti-C5aR Candidate

Phase I candidate already tested in rheumatoid arthritis could be used to optimize the activity of T cells and NK cells in the tumor microenvironment, either in combination with checkpoint inhibitors or as a solo agent.

PD-1 Sponsors Expand Into Bladder, Head & Neck Cancer

Merck claims first Phase III survival data in bladder cancer for Keytruda, while Bristol shows potential for immunotherapy combinations in bladder and head and neck cancers at the annual SITC meeting.

Patient-Centric: Evotec’s CSO Explains R&D Strategy

Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel